XML 113 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Investments - Additional Information (Detail) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Sep. 29, 2017
Jun. 30, 2021
Mar. 31, 2021
Jun. 30, 2020
Dec. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Jul. 31, 2021
Jul. 31, 2020
Apr. 30, 2020
Investments [Line Items]                    
Common stock Owned, Balance, Shares of Arbutus   16,013,540 16,013,540     16,013,540        
Preferred stock Owned, Balance, Shares of Arbutus   1,164,000 1,164,000     1,164,000        
Aggregate fair value investment   $ 180,359 $ 188,978     $ 188,978 $ 93,445      
Preferred stock issued and sold               639,140 639,140 13,411,311
Carrying value of long-term investment   $ 100,563 $ 100,563     $ 100,563 $ 0      
Common stock   222,669,799 222,669,799     222,669,799 214,879,058      
Series B Preferred Stock [Member]                    
Investments [Line Items]                    
Preferred stock issued and sold                 13,411,311  
Other Investments [Member]                    
Investments [Line Items]                    
Aggregate fair value investment   $ 11,900 $ 11,100     $ 11,100 $ 8,900      
Arbutus Biopharma Corporation [Member]                    
Investments [Line Items]                    
Premium on the conversion price, percentage 15.00%                  
Annual compounded conversion rate for preferred share   8.75% 8.75%     8.75%        
Conversion price   $ 7.13 $ 7.13     $ 7.13        
Closing price $ 6.20                  
Ownership interest, percentage         49.90%          
Maximum allowed ownership interest percentage         49.99%          
Aggregate fair value investment   $ 117,700 $ 129,400     $ 129,400 39,200      
Unrealized gain (loss) on investments   $ (11,700)   $ 31,500   $ 90,200 $ 99,900      
Closing price of common stock   $ 3.03 $ 3.33     $ 3.33 $ 1.01      
Equity method investment ownership percentage   32.00%                
Common stock     16,013,540     16,013,540 16,013,540      
Preferred stock     1,164,000     1,164,000 1,164,000      
Sio Gene Therapies Inc [Member]                    
Investments [Line Items]                    
Ownership interest, percentage   27.00%                
Aggregate fair value investment   $ 50,700 $ 48,500     $ 48,500 $ 45,300      
Unrealized gain (loss) on investments   $ 2,200   7,100   $ 3,200 $ 31,600      
Closing price of common stock   $ 2.73 $ 2.61     $ 2.61 $ 2.44      
Gain on deconsolidation             $ 107,300      
Datavant Holdings, Inc [Member]                    
Investments [Line Items]                    
Aggregate fair value investment   $ 99,000 $ 99,000     $ 99,000        
Gain on deconsolidation       $ 86,500   86,500        
Carrying value of long-term investment   $ 100,600 $ 100,600     $ 100,600        
Datavant Holdings, Inc [Member] | Series B Preferred Stock [Member]                    
Investments [Line Items]                    
Gross proceeds from issuance of stock                 $ 27,200 $ 27,200
Preferred stock issued and sold                 1,065,234 1,065,234
Total purchase price                   $ 2,500
Issued relating to the conversion of certain liability instruments                   1,800,253